Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13626793 | 0.90 | PDE3B (0.46) | ARALDH1A1SMN1; SMN2LMNAALDH1A3 | |
| SCHEMBL14531195 | 0.80 | GRIA2 (0.43) | ARALDH1A1LMNACYP11B1CYP11B2 | |
| SCHEMBL14531110 | 0.79 | GRIA2 (0.42) | ARALDH1A1LMNACYP11B1CYP11B2 | |
| SCHEMBL13140220 | 0.77 | AR (0.37) | ARCYP11B1CYP11B2BACE1 | |
| SCHEMBL14184764 | 0.75 | ALOX5AP (0.40) | CYP11B1CYP11B2PDE3BPDE3ABACE1 | |
| SCHEMBL13140418 | 0.74 | XDH (0.43) | ARCYP11B1CYP11B2 | |
| SCHEMBL13139806 | 0.74 | NR1H4 (0.38) | BACE1 | |
| SCHEMBL13140012 | 0.74 | AR (0.43) | ARPDE3BPDE3ABACE1 | |
| SCHEMBL13626769 | 0.73 | CYP11B1 (0.36) | ALDH1A1CYP11B1CYP11B2ALDH1A3MAPT | |
| SCHEMBL13139814 | 0.73 | CYP11B1 (0.40) | CYP11B1CYP11B2ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612108-B2 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | XDH, UACA, NUDT1 | AR 4192/4885ALDH1A1 424/4885SMN1; SMN2 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.